Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-11
2008-09-30
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211130, C514S218000, C514S253080, C514S254060, C514S379000
Reexamination Certificate
active
07429580
ABSTRACT:
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.
REFERENCES:
patent: 3819706 (1974-06-01), Mehta
patent: 3885046 (1975-05-01), Mehta
patent: 4089855 (1978-05-01), Chatterjie et al.
patent: 4172896 (1979-10-01), Uno et al.
patent: 4513006 (1985-04-01), Maryanoff et al.
patent: 4673679 (1987-06-01), Aungst et al.
patent: 4689332 (1987-08-01), McLaughlin et al.
patent: 4831031 (1989-05-01), Lowe et al.
patent: 4855306 (1989-08-01), Markstein et al.
patent: 5312925 (1994-05-01), Allen et al.
patent: 5358970 (1994-10-01), Ruff et al.
patent: 5403595 (1995-04-01), Kitchell et al.
patent: 5426112 (1995-06-01), Zagon et al.
patent: 5427798 (1995-06-01), Ludwig et al.
patent: 5486362 (1996-01-01), Kitchell
patent: 5512593 (1996-04-01), Dante
patent: 5541231 (1996-07-01), Ruff et al.
patent: 5719197 (1998-02-01), Kanios et al.
patent: 5731000 (1998-03-01), Ruff et al.
patent: 5763493 (1998-06-01), Ruff et al.
patent: 5817665 (1998-10-01), Dante
patent: 5856332 (1999-01-01), Dante
patent: 5958962 (1999-09-01), Dante
patent: 6004970 (1999-12-01), O'Malley et al.
patent: 6034091 (2000-03-01), Dante
patent: 6048322 (2000-04-01), Kushida
patent: 6071537 (2000-06-01), Shank
patent: 6071918 (2000-06-01), Cook
patent: 6110973 (2000-08-01), Young
patent: 6150366 (2000-11-01), Arenson et al.
patent: 6191117 (2001-02-01), Kozachuk
patent: 6197827 (2001-03-01), Cary
patent: 6210716 (2001-04-01), Chen et al.
patent: 6245766 (2001-06-01), Watsky
patent: 6248363 (2001-06-01), Mahesh et al.
patent: 6262049 (2001-07-01), Coffin et al.
patent: 6274579 (2001-08-01), Morgan et al.
patent: 6323236 (2001-11-01), McElroy
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6437147 (2002-08-01), Anderson et al.
patent: 6441038 (2002-08-01), Cook
patent: 6506799 (2003-01-01), Dasseux
patent: 6541478 (2003-04-01), O'Malley et al.
patent: 6548551 (2003-04-01), Hinz
patent: 6569449 (2003-05-01), Stinchcomb et al.
patent: 6686337 (2004-02-01), Connor
patent: 6713488 (2004-03-01), Sadee et al.
patent: 6905708 (2005-06-01), Li et al.
patent: 7109198 (2006-09-01), Gadde et al.
patent: 2001/0025038 (2001-09-01), Coffin et al.
patent: 2002/0025972 (2002-02-01), Hintz
patent: 2002/0037836 (2002-03-01), Henriksen
patent: 2003/0055008 (2003-03-01), Marcotte
patent: 2003/0144174 (2003-07-01), Brenna et al.
patent: 2003/0144271 (2003-07-01), Shulman
patent: 2004/0002462 (2004-01-01), Najarian
patent: 2004/0029941 (2004-02-01), Jennings
patent: 2004/0033965 (2004-02-01), Gadde et al.
patent: 2004/0106576 (2004-06-01), Jerussi et al.
patent: 2004/0122033 (2004-06-01), Nargund et al.
patent: 2004/0198668 (2004-10-01), Gadde et al.
patent: 2004/0242974 (2004-12-01), Glover
patent: 2004/0254208 (2004-12-01), Weber et al.
patent: 2005/0004106 (2005-01-01), Romano
patent: 2005/0026986 (2005-02-01), Maruani et al.
patent: 2005/0137144 (2005-06-01), Gadde et al.
patent: 2005/0143322 (2005-06-01), Gadde et al.
patent: 2005/0154002 (2005-07-01), Crooks et al.
patent: 2005/0181070 (2005-08-01), Gadde et al.
patent: 2005/0215552 (2005-09-01), Gadde et al.
patent: 2005/0277579 (2005-12-01), Krishnano et al.
patent: 2006/0009514 (2006-01-01), Gadde et al.
patent: 2006/0058293 (2006-03-01), Weber et al.
patent: 2006/0079501 (2006-04-01), Gadde et al.
patent: 2006/0100205 (2006-05-01), Weber et al.
patent: 2006/0122127 (2006-06-01), Rao et al.
patent: 2006/0142290 (2006-06-01), Weber et al.
patent: 2006/0160750 (2006-07-01), Gadde et al.
patent: 2006/0276412 (2006-12-01), Tollefson
patent: 0 442 769 (1991-08-01), None
patent: 2214241 (1996-06-01), None
patent: WO 90/13294 (1990-11-01), None
patent: WO 96/09047 (1996-03-01), None
patent: WO 99/37305 (1999-07-01), None
patent: WO 00/50020 (2000-08-01), None
patent: WO 00/51546 (2000-09-01), None
patent: WO 00/76493 (2000-12-01), None
patent: WO 01/62257 (2001-08-01), None
patent: WO 02/09694 (2002-02-01), None
patent: WO 03/013524 (2003-02-01), None
patent: WO 03/092682 (2003-11-01), None
patent: WO 03/097046 (2003-11-01), None
patent: WO 2004/009015 (2004-01-01), None
patent: WO 2004/024096 (2004-03-01), None
patent: WO 2004/050020 (2004-06-01), None
patent: WO 2004/096201 (2004-11-01), None
patent: WO 2004/110368 (2004-12-01), None
patent: WO 2004/110375 (2004-12-01), None
patent: WO 2005/000217 (2005-01-01), None
patent: WO 2005/049043 (2005-06-01), None
patent: WO 2006/017504 (2006-02-01), None
Tollefson et al. (Am J Psychiatry 1997, 154(4), 457-465).
Kanba et al. (Progress in Neuro-Psychopharmacology and Biological Psychiatry 1994, 18(4), 707-715).
Kimura et al. J Pharmacobiodyn 1992, 15(11), 631-9.
“A Novel Twist on Binge Eating Treatment” Primary Psychiatry; 6(10) 24-29 (1999).
Anderson, et al. Bupropion SR enhances weight loss Obesity R., vol. 10, N. 7, 2002, pp. 633-641, XP002351373.
Altman and Bland. “Standard Deviations and Standard Errors,” BMJ; 2005:331:903.
Appolinario et al. “Pharmacological Approaches in the Treatment of Binge Eating Disorder.” Current Drug Targets; 5:301-307 (2004).
Asconape. “Some Common Issues in the Use of Antiepileptic Drugs.” Seminars in Neurology; 22(1):27-39 (2002).
Atkinson, Clinical Guidelines on the identification, Evaluation, and Pharamacologic treatment of obesity in Adults, Online, Jul. 25, 2003, URL:http://www.endotext.org.obesity/obesity15b/obesity15b.htm.
Ayala, “Weight Loss Associated With the Administration of Zonisamide”, AES Proceedings, Epilepsia 41 (Suppl. 7) :99 (2000) -No. 2.041.
Ayala et al, “Weight Loss Associated With the Administration of Zonisamide”, A Compendium of Posters and Platform Sessions for ZONEGRAN™ and DIASTAT®, Presented at the Annual Meeting 2000 of the American Epilepsy Society, Dec. 1-6, 2000, Los Angeles, California.
Beelen, et al. “Asymptomatic QTC prolongation associated with queitiapine fumarate overdose in a patient being treated with risperidone” Human & Experimental Toxicology 92001) 20, 215-219.
Calabrese, et al. Letters to the Editors, “Lamotrigine and Clozapine for Bipolar Disorder” American J. of Psychiatry, vol. 157 9, Sep. 2000, 1523.
Carlsen, et al. “Evidence for dissociation of insulin-and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease” Diabetes Research and Clinical Practice Amersterdam, vol. 39, No. 1, Jan. 1998, pp. 47-54.
Carroll, F. I. J. Med. Chem , 46:10 (2003).
Chen, et al. “Synergistic Effects of Cannabiniod inverse agonist AM251 and opiod antagonist namefene on food intake”Brain Res. vol. 999, Jan. 2004, pp. 22-230.
Chengappa, et al. “Changes in body Weight and Body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review”Clinical Therapeutics, 24 (10) 1576-1584.
Cone, et al. “The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis,”Int'l Journal of Obesity, 25(5):S63-S67 (2001).
Dechant et al. Drugs, 41:225-253 (1991).
Dembowski, et al. “Successful Antimanic Treatment and Mood Stabilization with Lamotrigine, Clozapine, and Valproate in a Bipolar Patient after Lithium-induced Cerebellar Deterioration” Letter Pharmacopsychiatry, 2003; 36 83-86.
Delvin, et al. Int. J. Eating Disord. 28:325-332 (2000).
Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, Text Revision, p. 583-595 (2000).
Dursen, et al., Clozapine Plus Lamotrigine in Treatment-Resistant Schizophrenia, Arch Gen Psychiatry vol. 56, Oct. 1999, 950-951.
Dursun, et al. “Lamotrgine-Clozapine Combination in Refractory Schizophre
Gadde Kishore M.
Krishnan K. Ranga R.
Arnold Ernst V
Duke University
Knobbe Martens Olson and Bear LLP
Orexigen Therapeutics, Inc.
Richter Johann
LandOfFree
Compositions of an anticonvulsant and an antipsychotic drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions of an anticonvulsant and an antipsychotic drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of an anticonvulsant and an antipsychotic drug... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3984004